MIL:PHN

Pharmanutra S.p.A. · MIL · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 12:59 UTC

Last close

n/aEUR

Market data

35.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
27.3%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
15.2%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
12.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.29Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
1.4%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

Price is the furthest below its sector's middle: 0.20 against 0.36 on the market's range.

All from 100

lens 2 of 9

Sales

399

2016-12-31 to 2025-12-31100 at the start399

Sales: 100.00 on 2016-12-31 to 399.07 on 2025-12-31, up 299%.

Profit

519

2016-12-31 to 2025-12-31100 at the start519

Profit: 100.00 on 2016-12-31 to 519.42 on 2025-12-31, up 419%.

Shares in issue

138

2016-12-31 to 2025-12-31100 at the start138

Shares in issue: 100.00 on 2016-12-31 to 137.70 on 2025-12-31, up 38%.

Sales is at 399, Profit is at 519, Shares in issue is at 138, against 100 in 2016.

Sales is at 399, Profit is at 519, Shares in issue is at 138, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100399
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Profit, where the first year is 100519
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Shares in issue, where the first year is 100138
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR